Endogenous Marinobufagenin-Like Factor In Acute Plasma Volume Expansion

References

• Goto A, Yamada K, Yagi N, Yoshioka M, Sugimoto T. Physiology and pharmacology of eendogenous digitalis-like factors. Pharmacol. Rev. 1992; 44: 377–399
   PubMed Web of Science ®Google Scholar
• Schoner W. Endogenous digitalis-like factors. Clin Exp Hypertens 1992; A14: 767–856
   Google Scholar
• Doris P A. Regulation of Na,K-ATPase by endogenous ouabain-like materials. Proc. Soc. Exp. Biol. Med. 1994; 205: 202–212
   PubMed Web of Science ®Google Scholar
• Ludens J H, Clark M A, Du Charme D W, Lutzke B S, Mandel F, Mathews W R, Sutter D M, Hamlyn J M. Purification of an endogenous digitalislike factor from human plasma for structural analysis. Hypertension. 1991; 17: 923–929
   PubMed Web of Science ®Google Scholar
• Tymiak A A, Norman J A, Bolgar M, DiDonato G C, Lee H, Parker W L, Lo L-C, Berova N, Nakanishi K, Haber E, Haupert G TJ. Physicochemicalcharacterization of a ouabain isomer isolated from bovine hypothalamus. Proc. Natl. Acad. Sci. (USA). 1993; 90: 8189–8193
   PubMed Web of Science ®Google Scholar
• Ludens J H, Clark M A, Kolbasa K P, Hamlyn J M. Digitalis-like factor and ouabain-like compound in plasma of volume-expanded dogs. J Cardiovasc Pharmacol. 1993; 22(Suppl 2)S38–S41
   Google Scholar
• Doris P A. Ouabain in plasma from spontaneously hypertensive rats. Am. J. Physiol. 1994; 266: H360–H365
   PubMed Web of Science ®Google Scholar
• Barbier M, Shroter H, Meyer K, Schindler O, Reichstein T. DieBufogenine des Paratoidensekrets von Bufo marinus (L) Schneider. Helv. Chim. Acta. 1959; 42: 2486–2506
   Web of Science ®Google Scholar
• Chen K K, Kowarikowa A. Pharmacology and toxicology of toad venom. J. Pharmacol. Sci. 1967; 56: 1535–1542
   PubMed Web of Science ®Google Scholar
• Eliades D, Swindall B, Johnston J, Pamnani M B, Haddy F J. Hemodynamic effects of bufalin in the anesthetized dog. Hypertension. 1989; 13: 690–695
   PubMed Web of Science ®Google Scholar
• Pamnani M B, Chen S, Bryant H J, Schooley J F, Jr., Eliades D C, Yuan C M, Haddy F J. Effects of three sodium-potassium adenosine triphosphatase inhibitors. Hypertension. 1991; 18: 316–24
   PubMed Web of Science ®Google Scholar
• Kieval R S, Butler V P, Jr., Derguini F, Bruening R C, Rosen M R. Cellular electrophysiologic effects of vertebrate digitalis-like substances. J. Amer. Coll. Cardiol. 1988; 11: 637–43
   PubMed Web of Science ®Google Scholar
• Goto A, Yamada K, Ishii M, Sugimoto S, Yoshioka M. Immunoreactivity of endogenous digitalis-like factors. Biochem. Pharmacol. 1991; 41: 1261–1263
   PubMed Web of Science ®Google Scholar
• Sich B, Kirch R, Antolovic R, Schoner W. Demonstration ofinhibitors of the sodium pump in human plasma and bovine adrenal scross-reacting with proscillaridin A antibodies. The Sodium Pump, W Schoner, V Bamberg. Steinkopff Eds, Stuttgart 1994; 767–770
   Google Scholar
• Rasheed N, Doris P A. Production of cardiac glycoside-like materialby Y1 cells in serum-free conditions. FASEB J. 1995; 9: A637
   Google Scholar
• Bagrov A Y, Fedorova O V, Austin-Lane J L, Dmitrieva R I, Anderson D E. Endogenous marinobufagenin-like immunmoreactive factor and Na,K-ATPase inhibition during voluntary hypoventilation. Hypertension. 1995; 26: 781–788
   PubMed Web of Science ®Google Scholar
• Bagrov A Y, Fedorova O V, Dmitrieva R I, French A W, Anderson D E. Plasma marinobufagenin-like and ouabain-like immunoreactivity during salinevolume expansion in anesthetized dogs. Cardiovasc. Res. 1996; 31: 296–305
   PubMed Web of Science ®Google Scholar
• Fedorova O V, French A W, Anderson D E. Inhibition of erythrocyte Na,K-ATPase activity during anticipatory hypoventilation in micropigs. Am. J. Hypertens. 1996; 9: 1126–31
   PubMed Web of Science ®Google Scholar
• Bagrov A Y, Dmitrieva R I, Fedorova O V, Kazakov G P, Roukoyatkina N I, Shpen V M. Endogenous marinobufagenin-like immunoreactive substance-a possible endogenous Na,K-ATPase inhibitor with vasoconstrictor activity. Am. J. Hypertens. 1996; 9: 982–990
   PubMed Web of Science ®Google Scholar
• Bagrov A Y, Roukoyatkina N I, Pinaev A G, Dmitrieva R I, Fedorova O V. Effects of two endogenous Na,K-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur. J. Pharmacol. 1995; 274: 151–158
   PubMed Web of Science ®Google Scholar
• Komiyama Y, Mori T, Okuda K, Munakata M, Murakami T, Masuda M, Goto A, Yamada K, Talahashi H. Effects of intracerebroventricular administration of 6-hydroxydopamine on ouabain-like immunoreactivity in plasma and the hypothalamo-pituitary axis in rats. J Hypertens 1996; 14: 447–452
   PubMed Web of Science ®Google Scholar
• Lichtstein D, Gati I, Samuelov S, Berson D, Rosenman Y, Landau L, Deutsch J. Identification of digitalis-like compounds in human cataractous lenses. Eur J Biochem 1993; 19: 945–953
   Google Scholar
• Hilton P J, White R W, Lord G A, Garner G V, Gordon D B, Hilton M J, Forni L G, McKinnon W, Ismail F MD, Keenan M, Jones K, Morden W E. An inhibitor of the sodium pump obtained from human placenta. Lancet 1996; 348: 303–305
   PubMed Web of Science ®Google Scholar
• Bagrov A Y, Dmitrieva R I, Fedorova O V, Howald W, Hunter A P, Kazakov G P, Shpen V M. Evidence for a bufodienolide Na/K pump inhibitor inhuman urine. Am. J. Hypertens. 1996; 9: 133A
   Google Scholar
• Fedorova O V, Bagrov A Y. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin Evidence of interaction with different alpha-subunit isoforms. Am. J. Hypertens. 1997; 10: 929–935
   PubMed Web of Science ®Google Scholar
• Munzer J C, Daly S E, Jewell-Motz E A, et al. Tissue-and isoform-specific kinetic behavior of the Na,K-ATPase. J. Biol. Chem. 1994; 269: 16668–16676
   PubMed Web of Science ®Google Scholar